The Plastic Surgery Foundation
Log In Donate Now
 

Grants We Funded

Grant applicants for the 2022 cycle requested a total of over $2.9 million dollars. The PSF Study Section subcommittees of Basic & Translational Research and Clinical Research evaluated 115 grant applications on the following topics:

The PSF awarded research grants totaling almost $550,000 to support 19 plastic surgery research proposals.

ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.

Research Abstracts

Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.

Stem Cell Therapy for Tolerance Induction in Composite Tissue Allografts

Principal Investigator
Maria Siemionow MD, PhD

Year
2005

Institution
The Cleveland Clinic

Funding Mechanism
National Endowment

Focus Area
Technology Based

Abstract
Transplantation of composite tissue allografts (CTA) such as human hand, larynx, face, muscles, tendons nerves would have unlimited reconstructive applicability in plastic surgery if life-long immunosuppression would not be required for allograft survival. Different tolerance inducing strategies are tested in experimental models to bring CTA closer to clinical reality. Stem cell-based therapies included hematopoietic stem cell transplantation (HSCT) and adoptive immunotherapy constitutes promising strategies for tolerance induction in CTA and solid organ transplants. We have developed a model of tolerance induction in limb allograft transplants across major histocompatibility (MHC) barrier using 7-day protocol of combined anti-ab T-cell receptor (TCR) monoclonal antibody and CsA therapy (ab-TCRlCsA). Remarkably stable hematopoietic chimerism and a long-term tolerance (over 750 days) were achieved, suggesting that the presence of certain tissue compartments (stromal cells) may facilitate efficient engraftment of the HSC. We hypothesize that augmentation of the HSCT with stromal cells of donor origin is essential for improved engraftment and function of the HSCT. The intact bone marrow (BM) compartment of the vascularized graft (VG) model will be compared with non-vascularized bone marrow grafts (NVG) augmented with donor bone marrow stromal cell (BMSC) co-transplantation for chimerism induction. Once stable chimerism is induced, chimeric cells can be isolated, purified and propagated for adoptive transfer that will serve as a new therapeutic modality for allograft transplant recipients without the need for chronic immunosuppression. This innovative therapy may be directly applied to reconstructive procedures in Plastic Surgery, where shortage of autologous tissues will justify composite allografts transplantation.